A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors

Trial Profile

A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Amcasertib (Primary) ; Napabucasin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Boston Biomedical
  • Most Recent Events

    • 19 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Oct 2017.
    • 12 Sep 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Apr 2017.
    • 04 Apr 2016 Planned number of patients changed from 40 to 120 as reported by Clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top